Aptuit has extensive experience in analyzing large molecules such as proteins, peptides, and oligonucleotides using innovative techniques. Employing state of the art instrumentation, Aptuit’s highly qualified analysts were able to develop and validate appropriate methods for the analysis and full characterization of anti-sense oligonucleotides and their impurities.

Aptuit’s scientific expertise, integrated method development and validation services enabled the successful launching of the Phase I clinical trial of multiple anti-sense oligonucleotides.

We are particularly honoured to host this high level scientific conference in collaboration of IQPC this year.

This interactive event is great platform to meet and hear from 16+ leading industry experts, with exclusive case studies on biomarker and imaging strategies, as well as unique collaborations and how all of this has helped to drive early stage development.

Also, you can hear directly from the Medicines and Healthcare products Regulatory Agency (MHRA) about the new ICH S9 guidance.

For the complete speaker panel and agenda, you can download the event brochure here or visit the conference website.

As a valued customer of ours you can get a 15% discount for you to attend this industry-leading event. To achieve this discount please email info@aptuit.com and request the special discount code from our team.

For any additional information, email enquire@iqpc.co.uk or phone +44 (0) 207 368 9300 
 
Look forward to welcoming you to Verona.

SSCI a Division of Aptuit will be hosting a seminar at this event entitled Cocrystals of Nutraceuticals

To arrange a meeting with an Aptuit expert please email info@aptuit.com

For the past four years, CBI has been the recognized leader in Clinical Supply Chain Management events.  Known for our high level programming and robust networking opportunities. In 2010, the 5th Clincal Supply Chain Management Conference will feature an esteemed lineup of industry experts and fresh faces with novel perspectives.

Aptuit are proud to sponsor this event and will be exhibiting. To speak with an Aptuit representative or prearrange a meeting please contact info@aptuit.com

This conference is known for providing industry with regulatory guidance, operational efficiencies and emerging technology for global supply chain excellence

Aptuit will be attending this event and will have an exhibition booth.

To arrange a meeting with us please send an e-mail to: info@aptuit.com

This meeting provides an extremely valuable and truly unique opportunity for Xenobiotic researchers to gather, exchange ideas and expertise. In addition to an outstanding scientific program, which features preclinical aspects, clinical aspects, and new applications of drug development in the 21st century, the ISSX Meeting provides you with access to state-of-the-art exhibits and poster presentations.

Aptuit will be exhibiting at this event. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com

At Aptuit we are dedicated to Science. As the global leader in integrated pharmaceutical serivices, we provide the very best world class drug development and drug discovery solutions. Supported by our industry renowned experts, we are able to offer advice and expertise to help you meet your milestones quickly and efficiently.

To demonstrate our commitment to science we are offering *FREE 10 minute consultation sessions with one of our experts in API and Solid State Chemistry. Drop by our AAPS booth 1339 and let our experts offer advice to help you solve your drug development challenges.

Visit the Aptuit theatre to learn more about our dedication to science and the services we provide by attending one of our presentations:-

Monday Nov 9th
1330pm - General overview of Aptuit Services
1430pm - Amorphous
1515pm - CoCrystals
1600pm - Biochemistry

Tuesday Nov 10th
0930am - Amorphous
1030am - CoCrystals
1115am - Biochemistry
1330pm - General overview of Aptuit Services
1430pm - IP
1515pm - Analytical

Wednesday Nov 11th
0930am - CoCrystals
1030am - Biochemistry
1115am - General overview of Aptuit Services
1330pm - Amorphous

A poster on The Investigation of Protein-Sugar Interaction in the Solid State, authored by H. Zhang, I. Ivanisavic, P.A. Tishmack, D. Sedlak, A.T. Gilkison and S.J Bogdanowich-Knipp will be available for viewing on Wednesday, November 11 from 8:00am to 12:00pm. The poster will be located in the west exhibit hall A.

Visit Aptuit at booth #1339. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com

*Subject to availability

Aptuit will host presentations titled

Aqueous solubility of nutraceutical cocrystals and Polymorphic cocrystals

Times to be confirmed. 

Visit Aptuit at booth #2237. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com

2011 AAPS Annual Meeting and Exposition General Sessions Look Toward the Next 25 Years
The AAPS, currently celebrating its 25th anniversary, has themed the keynote and plenary sessions for the Annual Meeting The Next 25 Years. 

Thousands of scientists will converge in Washington to share various perspectives, ideas and cultural learnings in order to improve health through advances in pharmaceutical sciences.

 
If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com

Aptuit will be exhibiting during the exposition which will run on 17-18th May.

To speak with an Aptuit representative please contact info@aptuit.com to prearrange a meeting

Welcome to the 4th annual ADMET Europe conference and exhibition. This year's event will be held in Munich, Germany.

The conference will be co-located with MedChem Europe, Pharma Outsourcing Congress and 1st International Conference of The Flow Chemistry Society.

Agenda Topics Include

-ADMET/PK/PD Modelling
-ADME Optimisation
-Drug-drug Interaction and Tox Prediction
-In vivo and in vitro Assays

Aptuit will be exhibiting at this event with a stand.

If you wish to meet with us during the event, please send an e-mail to info@aptuit.com

Aptuit Consutling will attend this conference and have a table top display. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuitconsulting.com.

SSCI has devoted considerable research and development resources in order to gain a better understanding of amorphous materials and amorphous dispersions. These efforts have resulted in innovative techniques to study and characterize these materials, from generation, to stability, through to scale up. We invite you to join us for a one-day seminar to hear our world renowned experts, including Dr. Jan-Olav Henck, Senior Director of SSCI, discuss the viability and use of amorphous dispersions in drug development as well as the research that has been carried out with regards to amorphous dispersions that is unique to SSCI.

We are honored to have Stephen R. Byrn, Ph. D, Professor of Medicinal Chemistry at Purdue University, discuss regulatory issues related to drug development of amorphous dispersions. Our scientists will also be joined by Eyal Barash, Chief Patent Counsel to Aptuit, to discuss IP issues pertaining to the development of amorphous dispersions and materials.

Seminar Information:Cost: $200Thursday, April 1, 2010 - 8:00 am to 4:30 pmLe Méridien Cambridge-MIT20 Sidney Street Cambridge, Massachusetts 02139

Click for more info and to register

Questions? Call: Colleen Bleczinski at 800-375-2179 x6905Email: colleen.bleczinski@aptuit.com

Also hear from industry leaders as to which amorphous forms of drugs the have developed and why. Learn from their case studies how they stabilised and controlled these forms and what they are used for now.

Dr Igor Ivanisavic will be speaking at this event and we will also have an exhibition stand. To pre-arrange a meeting with an Aptuit representative please contact info@aptuit.com

Characterization of Biologicals by Conventional and Solid State Analytical Techniques

Presented by: Susan Bogdanowich-Knipp, Ph.D., Research Director, Aptuit
October 7, 2010
10:00 am, Central Daylight Time
Click here to register

Pharmaceutical Applications of Calorimetry

Presented by: Erich Gundlach, Senior Scientist, Aptuit
October 14, 2010
10:00 am, Central Daylight Time
Click here to register

Quantitative Solid-State Method Development and Validation in Accordance with ICH Q2(R1)

Presented by Donald Hallenbeck, Senior Research Investigator, Aptuit
October 21, 2010
10:00 am, Central Daylight Time 
Click here to register

Patenting Cocrystals, Crystalline Forms and Disordered Solids - How to Think about Intellectual Property with Solid Forms

Presented by Eyal Barash, Chief Patent Counsel of Aptuit
October 28, 2010
10:00 am, Central Daylight Time
Click here to register

Aptuit scientific experts will discuss the current approach for the preclinical development of safer and more effective Gene Therapy Medicinal Products that are compliant with current and pending legislations and guidelines, with a particular focus on some of the special investigations that are unique to GTMPs development. An overview of the most representative techniques and their applications for the preclinical development of GMTPs will be presented.

This International trade show is the largest congregation of the biotech fraternity in India. Over 600 conference delegates and 5000 business visitors from across India and overseas will allow unrivaled networking and business opportunities -

Aptuit Laurus will be in attendance at this show on Stand number 4. To pre-arrange a meeting with one of our representatives email info@aptuit.com

Accelerated Virtual Drug Development:
Given the current and foreseeable economic environment, companies from early stage and emerging biotech's to large pharmaceutical firms are being forced to do more with less. In an effort to reduce and/or minimize direct expenditures, outsourcing has become part of many a company’s development strategy eliminating the need to incur long term funding commitments for infrastructure. Numerous options now exist for outsourcing but too often lack integration resulting in limited productivity gains. To address this issue there is a paradigm shift underway in drug development by some in the pharmaceutical industry from what was a FIPCO (fully-integrated pharmaceutical company) model to a VIPNET (virtually-integrated pharmaceutical network) model. Creation of novel business arrangements between sponsors and vendors are giving rise to accelerated development in a virtual world where realization of both time and cost savings is clearly apparent. This seminar will describe the benefits and challenges of virtual drug development from the perspective of a virtual company along with a novel approach accomplished through a Virtual Drug Development Agent and show how it is created, and operated along with its features and benefits.

This Session will bring together a panel of experts with different perspectives from biotech, venture capital and virtual organizations from the Bay area -with experience and understanding of how to employ new business arrangements and strategies to sustain growth and drive value in a virtual world.

Moderator:
William D. Kerns DVM, MS, DACVP,President, Aptuit Consulting Inc

Panelists:
Robert G. Urban, Ph.D., Executive Director,
David H. Koch Institute for Integrative Cancer Research, MIT
Johnson Y.N. Lau, M.B., B.S., M.D., F.R.C.P., Chairman, XenoBiotic Laboratories, Chairman, Kinex Pharmaceuticals, Chairman, XBL China
Andrew A. Protter, Ph.D., Vice President, Preclinical Development, Medivation, Inc.
Kenneth M Ferguson, Ph.D., President and CEO, Imvaxyn, Inc

    ·   Evaluate the risk of not considering commercialization activities until late-stage clinical development.

    ·   Examine how organizations use scenario planning to develop effective supply chain strategies.

    ·   Understand how to use supply chain strategy to avoid being forced into inflexible and expensive decisions.

Featuring EBD Group’s sophisticated, web-based partnering system partneringONE®, the event enables delegates to efficiently identify, meet and get partnerships started with companies across the life science value chain, from large biotech and pharma companies to financiers and innovative start-ups.

Aptuit will be attending this event

To arrange a meeting with us please send an e-mail to: info@aptuit.com

This International Stem Cell Meeting is a prestigious international event bringing together world-renowned scientists at the frontier of embryonic and adult stem cell research. -

Aptuit will be exhibiting at this event. To pre-arrange a meeting with an Aptuit representative please email info@aptuit.com

This International Stem Cell Meeting is a prestigious international event bringing together world-renowned scientists at the frontier of embryonic and adult stem cell research. -

Aptuit will be exhibiting at this event. To pre-arrange a meeting with an Aptuit representative please email info@aptuit.com

Aptuit and Aptuit Consulting present a webinar exploring the regulatory and scientific aspects of non-clinical biosimilar development. The webinar will include an introduction to biosimilars or follow on biologics and their current development status. Up to date information will be presented on current biosimilar guidelines and the challenges of working in an uncertain global regulatory environment will be discussed. The webinar will focus on non-clinical development of biosimilar monoclonal antibodies, covering key aspects of pharmacokinetics, safety, immunogenicity and pharmacodymanic study designs.

Thursday, October 28, 2010
10:00 am, Central Daylight Time
Click here to register

Questions? Email ask@aptuit.com

Sohuset Conference Centre, Copenhagen, Denmark

Aptuit will be attending this event. To pre arrange a meeting with an Aptuit representative please email info@aptuit.com

BioTrinity 2011 will be the Largest Gathering of the UK's Bioindustry (Apr 12-14), and is Europe's Fastest Growing Biopartnering and Investment Conference, facilitating more meetings with more investors than any other UK conference. BioTrinity 2011 will feature a showcase of the best of the UK's emerging and clinical stage companies. Big pharma participating in 2010 included Pfizer, Merck, Novartis, GSK, AstraZeneca, BMS, Takeda, Boehringer Ingelheim, Shire, Teva, OSI,Genzyme, UCB, Alliance Pharma, Daiichi Sankyo and Ranbaxy. You can partner with the best at BioTrinity.

Aptuit will be attending this event

To arrange a meeting with us please send an e-mail to: info@aptuit.com

This Symposium is expected to attract over 1500 scientists from across all departments and facilities within BMS worldwide (well over 20% of the BMS Worldwide R&D staff). The focus of the symposium is their proprietary presentation of over 850 internal posters.

Aptuit will be exhibiting at this event, if you would like to know more about Aptuit and pre arrange a meeting with an Aptuit representative please email info@aptuit.com

Aptuit will be attending this event and will be exhibiting

For more information, please send us an e-mail at info@aptuit.com

ChemOutsourcing offers a unique conference featuring over 100 speakers, mostly from pharma and biotech companies, and sessions cover the chemical gamut from discovery, pre-clinical development, and commercial scale manufacturing. Milligrams to tons. The event keeps apace the fast-globalizing chemical industry so you can gather critical information and contacts you need for your business.

To prearrange an meeting with an Aptuit representative please email info@aptuit.com

The annual ChemOutsourcing Show has emerged in the past 2 years as a uniquely useful pharmaceutical industry-specific meeting for everyone who attends it. The show attracts small pharmaceutical and biotech company sourcing management plus a large assembly of suppliers from around the world. A marked increase in the number of biotech company sourcing management has marked the past 2 years.

ChemOutsourcing offers a unique conference featuring over 100 speakers, mostly from pharma and biotech companies, and sessions cover the chemical gamut from discovery, pre-clinical development, and commercial scale manufacturing. Milligrams to tons. We keep apace the fast-globalizing chemical industry so you can gather critical information and contacts you need for your business.

Aptuit will be attending this event 

To arrange a meeting with us please send an e-mail to: info@aptuit.com

Expert speakers will address the issues surrounding the management of Global Clinical Trials, including what you need to know to meetthe challenges. You will also have an opportunity to network with colleagues, industry resources and question our experienced panel.

For more information, click here.

Questions? Email ask@aptuit.com

]]>Fri, 04 Apr 2008 16:00:00 GMTAptuit Events Hyatt Regency Jacksonville Riverfront, Jacksonville, FL

Global Clinical Supplies Group is a forum for open discussion to share knowledge and industry best practices for clinical supply and related professionals.

This conference showcases this open discussion along with a variety of exhibitors and presentations designed to educate attendees.

Aptuit will be exhibiting at this event with a stand.

If you wish to meet with us during the event, please send an e-mail to info@aptuit.com

• Exploring trial/molecule specific facility licenses to store and distribute narcotic clinical trial materials
• Moving clinical trial materials between countries: specific import and export licenses needed and obstacles faced
• Controlled drug capacity at depots
• Analyzing different country requirements for different schedules of controlled drugs

• Exploring trial/molecule specific facility licenses to store and distribute narcotic clinical trial materials
• Moving clinical trial materials between countries: specific import and export licenses needed and obstacles faced
• Controlled drug capacity at depots
• Analyzing different country requirements for different schedules of controlled drugs

To set up a meeting with an Aptuit representative at this event please email info@aptuit.com

Translating Co-Crystal Properties, Screening and Design into Commercial Success

Pharmaceutical Co-Crystals 2008, is the only conferences focusing on purely co-crystal drugs, and will provide you with the unique opportunity to network with individuals working within the field, with ten networking opportunities, you can really maximise your time out of office by gaining answers to all those niggling research questions.

Learn form the successes and failures of others on how to incorporate to best translate co-crystal properties, screening and design, into a commercially successful product.

Aptuit is a participating sponsor of this event.

Dr Scott Childs, Snr Research Chemist, Aptuit, Inc will be presenting on the topic - Is There Anything New We Can Learn From Carbamazepine? Optimising Co-Crystal Screening Strategies Using Phase Diagrams And The Analysis Of A Family Of Related Crystal Structures Using Materials Mercury

To pre-arrange a meeting with an Aptuit representative please email info@aptuit.com

Controlled Release Society presents its annual meeting where we will hear from no less than 1000 scientific contributors and promises to be some notable star performers such as: Gordon Amidon of the University of Michigan, Walt Orenstein of the Bill and Melinda Gates Foundation, and two senior pharmaceutical industry executives: Gordon Muirhead of GSK and Michael Hutchison of AstraZeneca.

Aptuit will be attending this event and will have an exhibition booth.

To arrange a meeting with us please send an e-mail to: info@aptuit.com

Cool Chain professionals have come to rely on the annual Cool Chain Europe conference and networking forum for the latest information, best practices and solutions for monitoring and controlling temperatures of biopharma products and clinical supplies.

Aptuit will have a representative available at this event. To pre arrange a meeting please email info@aptuit.com

Aptuit will be exhibiting in Hall 4.0 on stand 40H13. To pre-arrange a meeting with one of our representatives please contact info@aptuit.com

Gathering in Madrid, this three day event will attract everyone from manufacturers and purchasers of fine chemicals and pharmaceuticals to solution providers, all in search of the latest industry developments.

Aptuit will be exhibiting in Hall 3.0 on stand 3F56. To pre-arrange a meeting with one of our representatives please contact info@aptuit.com

CPhI Worldwide 2011 is an unrivalled networking event with 28,500 attendees from 140 countries creating a unique environment where delegates can meet, learn, network and share ideas with each other.
Make sure you attend the world's leading pharmaceutical networking event. Meet Aptuit face-to-face, stay informed about the latest industry trends and remain one step ahead of a constantly changing pharma market.

To pre-arrange a meeting with an Aptuit expert, please e-mail: info@aptuit.com

For more information on Aptuit at CPhI 2011 please visit our microsite at: http://www.aptuit.com/cphi/

- Introduce their company to the Japanese market
- Reinforce their company's position in the Japanese market
- Bolster Japanese partner/distributor marketing activity
- Launch new products in the Japanese market
- Make new contacts and expand their Japanese network

Aptuit will be exhibiting at this event, if you would like to set up a meeting with and Aptuit representative, please email info@aptuit.com

 CPhI Japan is the biggest pharmaceutical ingredients exhibition held in Japan, can only partly explain its success. It's the combination of high quality organisation and a high quality targeted audience that makes CPhI so appealing to companies to participate in this high profile event.The success in attracting such a large number of potential Japanese business-partners makes CPhI Japan especially compelling for companies from other parts of the world, since it provides them with a platform to:

- Introduce their company to the Japanese market

- Reinforce their company's position in the Japanese
  market

- Bolster Japanese partner/distributor marketing
  activity

- Launch new products in the Japanese market

- Make new contacts and expand their Japanese
  network

And all this through making contact with Japanese companies that you will NOT meet at CPhI Worldwide! 

Aptuit will be exhibiting at this event. Please visit us on stand number L15. To pre arrange a meeting with an Aptuit representative please email info@aptuit.com

Gathering in France, this three day event will attract everyone from manufacturers and purchasers of fine chemicals and pharmaceuticals to solution providers, all in search of the latest industry developments.

Aptuit will be exhibiting in Hall 5A on stand 5P34. To pre-arrange a meeting with one of our representatives please contact us

Please visit our CPhI 2010 microsite for more information

Clinical Trials in Emerging Countries

Boston, September 17, 2008, 11:30am – 2:30pm

Marriott Boston Cambridge, Two Cambridge Center, 50 Broadway, Cambridge, MA 02142

Expert speakers will address the issues surrounding the management of Global Clinical Trials, including what you need to how to meet the challenges. You will also have an opportunity to network with colleagues, industry resources and question our experienced panel.

To attend please contact Erica Maurerat erica.maurer@aptuit.com. Seminarswill also takeplace in Boston, Philadelphia, San Fransico, and San Diego.

Speakers:

Joa Haas, Aptuit

Overview of industry, outsourcing, and emerging countries

Should my company be looking to emerging markets for clinical trials? What is the current status

and future trends of trials being conducted in India and China?

Aptuit’s introduction to the day will offer information to help you decide if this is a strategy you should consider for your trials.

Angus MacLeod, Aptuit

Distribution strategy in emerging countries

Central storage and distribution or local depots? What works best and why?

Aptuit’s presentation will provide information regarding the options available to help you develop a distribution strategy that fits your style and current trial needs.

Andrew Hecht, World Courier

Keys to shipping, importing, and exporting in emerging countries

The successful delivery of investigational drugs from origin to patient is more complicated, with increased scrutiny placed on in-transit temperature control and monitoring when the clinical trials are in emerging markets.

World Courier's presentation will offer insight and highlight trends, import challenges and regulatory changes.

Donald Nolde, Cold Chain Technologies

Cold Chain management in emerging markets

Maintaining temperature and product integrity shipping in extended travel lanes to emerging markets poses more challenges than domestic distribution. Carriers, agents, brokers and customs are all variables making a robust solution essential.

The presentation by Cold Chain Technologies will look at packaging options for all temperature ranges including CRT and discuss trends in package qualifications and temperature profiles.

Clinical Trials in Emerging Countries

Montreal, September 12, 2008, 11:30am – 2:30pm

Hotel Omni Mont-Royal, 1050 ouest, rue Sherbrooke, Montreal (Quebec) H3A 2R6

Expert speakers will address the issues surrounding the management of Global Clinical Trials, including what you need to how to meet the challenges. You will also have an opportunity to network with colleagues, industry resources and question our experienced panel.

To attend please contact Erica Maurerat erica.maurer@aptuit.com. Seminarswill also takeplace in Boston, Philadelphia, San Fransico, and San Diego.

Speakers:

Joa Haas, Aptuit

Overview of industry, outsourcing, and emerging countries

Should my company be looking to emerging markets for clinical trials? What is the current status

and future trends of trials being conducted in India and China?

Aptuit’s introduction to the day will offer information to help you decide if this is a strategy you should consider for your trials.

Angus MacLeod, Aptuit

Distribution strategy in emerging countries

Central storage and distribution or local depots? What works best and why?

Aptuit’s presentation will provide information regarding the options available to help you develop a distribution strategy that fits your style and current trial needs.

Andrew Hecht, World Courier

Keys to shipping, importing, and exporting in emerging countries

The successful delivery of investigational drugs from origin to patient is more complicated, with increased scrutiny placed on in-transit temperature control and monitoring when the clinical trials are in emerging markets.

World Courier's presentation will offer insight and highlight trends, import challenges and regulatory changes.

Philadelphia, September 19, 2008, 11:30am – 2:30pm
The Valley Forge Scanticon, Hotel and Conference Center, 1210 First Avenue, King of Prussia, PA 19406

To attend please contact Erica Maurerat erica.maurer@aptuit.com. Seminarswill also takeplace in Montreal, Boston, San Fransico, and San Diego.

Expert speakers will address the issues surrounding the management of Global Clinical Trials, including what you need to know to meet the challenges. You will also have an opportunity to network with colleagues, industry resources and question our experienced panel.

Joa Haas, Aptuit
Overview of industry, outsourcing, and emerging countries
Should my company be looking to emerging markets for clinical trials? What is the current status and future trends of trials being conducted in India and China?
Aptuit’s introduction to the day will offer information to help you decide if this is a strategy you should consider for your trials.

Angus MacLeod, Aptuit
Distribution strategy in emerging countries
Central storage and distribution or local depots? What works best and why?
Aptuit’s presentation will provide information regarding the options available to help you develop a distribution strategy that fits your style and current trial needs.

Mike Sweeney, World Courier
Keys to shipping, importing, and exporting in emerging countries The successful delivery of investigational drugs from origin to patient is more complicated, with increased scrutiny placed on in-transit temperature control and monitoring when the
clinical trials are in emerging markets.
World Courier's presentation will offer insight and highlight trends, import challenges and regulatory changes.

Donald Nolde, Cold Chain Technologies
Cold Chain management in emerging markets
Maintaining temperature and product integrity shipping in extended travel lanes to emerging markets poses more challenges than domestic distribution. Carriers, agents, brokers and customs are all variables making a robust solution essential.
The presentation by Cold Chain Technologies will look at packaging options for all temperature ranges including CRT and discuss trends in package qualifications and temperature profiles.

Clinical Trials in Emerging Countries

San Diego, September 26, 2008, 11:30am – 2:00pm

San Diego Marriott, 4240La Jolla Village Drive, La Jolla, CA 92037

Expert speakers will address the issues surrounding the management of Global Clinical Trials, including what you need to how to meet the challenges. You will also have an opportunity to network with colleagues, industry resources and question our experienced panel.

To attend please contact Erica Maurerat erica.maurer@aptuit.com. Seminarswill also takeplace in Boston, Philadelphia, San Fransico, and San Diego.

Speakers:

Joa Haas, Aptuit

Overview of industry, outsourcing, and emerging countries

Should my company be looking to emerging markets for clinical trials? What is the current status

and future trends of trials being conducted in India and China?

Aptuit’s introduction to the day will offer information to help you decide if this is a strategy you should consider for your trials.

Angus MacLeod, Aptuit

Distribution strategy in emerging countries

Central storage and distribution or local depots? What works best and why?

Aptuit’s presentation will provide information regarding the options available to help you develop a distribution strategy that fits your style and current trial needs.

Kimberly G Rossall,World Courier

Keys to shipping, importing, and exporting in emerging countries

The successful delivery of investigational drugs from origin to patient is more complicated, with increased scrutiny placed on in-transit temperature control and monitoring when the clinical trials are in emerging markets.

World Courier's presentation will offer insight and highlight trends, import challenges and regulatory changes.

Donald Nolde, Cold Chain Technologies
Cold Chain management in emerging markets
Maintaining temperature and product integrity shipping in extended travel lanes to emerging markets poses more challenges than domestic distribution. Carriers, agents, brokers and customs are all variables making a robust solution essential.
The presentation by Cold Chain Technologies will look at packaging options for all temperature ranges including CRT and discuss trends in package qualifications and temperature profiles.

Clinical Trials in Emerging Countries

San Francisco, September 24, 2008, 11:30am – 2:00pm

Embassy Suite, 250 Gateway Blvd, South San Francisco, CA 94080

Expert speakers will address the issues surrounding the management of Global Clinical Trials, including what you need to how to meet the challenges. You will also have an opportunity to network with colleagues, industry resources and question our experienced panel.

To attend please contact Erica Maurer at erica.maurer@aptuit.com. Seminars will also take place in Boston, Philadelphia, San Fransico, and San Diego.

Speakers:

Joa Haas, Aptuit

Overview of industry, outsourcing, and emerging countries

Should my company be looking to emerging markets for clinical trials? What is the current status

and future trends of trials being conducted in India and China?

Aptuit’s introduction to the day will offer information to help you decide if this is a strategy you should consider for your trials.

Angus MacLeod, Aptuit

Distribution strategy in emerging countries

Central storage and distribution or local depots? What works best and why?

Aptuit’s presentation will provide information regarding the options available to help you develop a distribution strategy that fits your style and current trial needs.

Teri Gevry, World Courier

Keys to shipping, importing, and exporting in emerging countries

The successful delivery of investigational drugs from origin to patient is more complicated, with increased scrutiny placed on in-transit temperature control and monitoring when the clinical trials are in emerging markets.

World Courier's presentation will offer insight and highlight trends, import challenges and regulatory changes.

Donald Nolde, Cold Chain Technologies
Cold Chain management in emerging markets
Maintaining temperature and product integrity shipping in extended travel lanes to emerging markets poses more challenges than domestic distribution. Carriers, agents, brokers and customs are all variables making a robust solution essential.
The presentation by Cold Chain Technologies will look at packaging options for all temperature ranges including CRT and discuss trends in package qualifications and temperature profiles.

Including:

• Building and Maintaining Effective Communications with Clinical Operations
• Understanding the Roles and Responsibilities of the Qualified Person (QP)

OBJECTIVES: At the conclusion of this meeting, participants will be able to:

• Identify the challenges in building and maintaining effective communication with Clinical Operations.
• Identify the responsibilities of the QP.
• List at least three ways to positively influence their Clinical Trial Supply delivery.

LOCATION: HILTON LA JOLLA TORREY PINES, LA JOLLA, CA

For more information please contact Sarah Nackson, Coordinator, Training Programs & CSSG at 908-233-4508 or snackson@jeiven.com

This webinar will provide an overview of the Dried Blood Spot (DBS) technique and its benefits in pre-clinical and clinical studies.

DBS is a technique that allows simple collection, shipping, and storing of blood samples. This technique requires spotting tiny blood volumes from a finger or heel prick onto absorbent filter paper that is dried and stored at room temperature. DBS has many advantages over conventional blood or plasma samples, including improved preclinical data. Join our webinar to learn how dried blood spot technology can benefit your drug development from both a preclinical and clinical perspective.

Luca Ferrari, Head of Bioanalysis at Aptuit Verona, will present his expertise and experience in the development, validation and application of highly sensitive automated dried blood spot assays.

Wednesday, April 6, 2011
11:00 am EST
Click here to register

Founded in 1890, the Drug, Chemical & Associated Technologies Association, Inc. (DCAT) is a non-profit business development association whose membership is comprised of companies that manufacture, distribute or provide services to the pharmaceutical, chemical and related industries. The Association provides services, programs and activities designed to support the business development objectives of its membership.

Steeped in a rich history and tradition, the DCAT Annual Dinner has proven time and time again to be a valued and well-regarded event within the pharmachem industry and certainly not something to be missed. 

Aptuit will be be particpating at this event and will have a dinner table in the grand ballroom, #106

If you wish to meet with us at this event, please send an e-mail to info@aptuit.com

The premiere European conference for the presentation of lectures and posters relating to the development of inhalers for the treatment of both respiratory diseases and also for systemic drug delivery.

For the fifth year running the DDL Conference will return to Edinburgh. The meeting format will consist of a series of themed podium sessions on the science, technology and regulation of drug delivery to the lungs, plus a combined display area for scientific posters and supplier exhibits.

Aptuit will be exhibiting at this event, to pre-arrange a meeting with one of our representatives please email info@aptuit.com

The Annual Meeting welcomes attendees from all geographic locations, professional categories, and levels of responsibility – making it the perfect venue for blending multidisciplinary learning with global networking opportunities.

Geographic Locations

• Africa
• Asia
• Australia
• Europe
• North America
• South America

Prefessional Categories

• Academic
• Government
• Healthcare
• Industry

Levels of Responsibility

• Departmental, divisional or group functions
• Overall organizational functions
• Specialized function or job within a group or division

The Annual Meeting welcomes attendees from all geographic locations, professional categories, and levels of responsibility – making it the perfect venue for blending multidisciplinary learning with global networking opportunities.

Geographic Locations

• Africa
• Asia
• Australia
• Europe
• North America
• South America

Prefessional Categories

• Academic
• Government
• Healthcare
• Industry

Levels of Responsibility

• Departmental, divisional or group functions
• Overall organizational functions
• Specialized function or job within a group or division

Aptuit will be exhibiting at this event. To meet with one of our industy renowned experts email info@aptuit.com

Drug Delivery and Formulation America is a networking opportunity for both scientific and business leaders involved in drug delivery and formulation to discuss the current challenges and new strategies to succeed in this evolving area.

This three stream event allows delegates the opportunity to focus on their main area of interest, whilst exchanging information with colleagues from biopharmaceutical formulation and delivery. The key issues include:

-Small molecule formulation – enhancing solubility and bioavailability 
-Biologic formulation – improving stability and preventing aggregation
-Drug delivery partnerships – evaluating potential of new drug delivery technologies

Aptuit will be sponsoring this event with a table

If you wish to meet with us during the event, please send an e-mail to info@aptuit.com

• Understand guidelines and deadlines set for electronic submissions
• Learn about best practices associated with eCTD document management
• Find out how to manage scientific information in electronic form
• Discover the latest methods on how to submit and track your documents
• Benefit from our experience on how to transfer legacy products to the eCTD format
• Integrate eSubmissions into Regulatory document life cycle management

Our expert Regulatory professionals want to help you successfully produce your eCTD for submission to regulatory authorities

Aptuit Consulting can be a vital asset to your Regulatory Team’s strategy. Sign up for this free webinar today.

For more information call us at 781 778 0418 or email us at consultinginfo@aptuit.com

Aptuit will be exhibiting at this event. To prearrange a meeting with an Aptuit representative please email info@aptuit.com

Aptuit will be exhibiting at this event. To prearrange a meeting with an Aptuit representative please email info@aptuit.com

Speakers:

Mauro Corsi, Head of In vitro Pharmacology, Aptuit, Verona, Italy
Pasquina Marzola, Associate Professor of Experimental Physics, University of Verona, Verona, Italy
Pasquale Fiengo, Scientist, Pharmacology Department, Siena Biotech, Siena, Italy

Click here to register!

The FT Global Pharmaceutical and Biotechnology Conference provides a unique platform to air your views on the latest industry developments and prepares you to better identify, anticipate and meet tomorrow’s challenges head on.

Visit Aptuit at booth #1242. To pre-arrange a meeting with one of our representatives, please visit our dedicated Informex Microsite at www.aptuit.com/informex

Aptuit will also be hosting an exhibitor showcase which will take place on Monday February 7th at 1020am in room 211.

Panel Session - Wednesday 9th February, 2011 at 9am

Sponsored by Aptuit, Inc.

The Evolution of Chemistry Outsourcing: How Drug Developers are Leveraging Partners to Drive Increased Productivity

This interactive conference session will explore how outsourcing of chemistry services is evolving and is poised to deliver increased value within the context of new models of R&D. The session will include discussion and audience feedback on whether outsourcing of chemistry services is becoming a more strategic initiative, integrated with other elements of the development process, or if it remains a relatively tactical activity. 

Moderator:

Jim Miller,
President, PharmSource

Panelists:

Stuart Needleman,
President, API Development and Manufactuing,
Aptuit, Inc.

Terri Cooper,
PhD, Managing Director,
Deloitte Consulting LLP

Richard Couch,
Vice President, Non Clinical Development,
Shire Pharmaceuticals

Andreas Woppmann,
Vice President, Manufacturing Operations,
Ariad Pharmaceuticals

And don't forget to stop by Aptuit's Exhibitor Showcase, Presentation by Jan-Olav Henck, Chief Scientific Officer, Monday February 14 at 3pm in meeting room 267.

Education sessions follow seven tracks of interest: Regulatory, Innovation, Manufacturing Operations, Engineering Design, Investigational Products, Project Management, and Efficient and Effective Compliance. Networking activities, exhibits, and special events allow for one-on-one time with colleagues for further knowledge and best practice sharing.

Aptuit will attend this meeting

• 18th Annual Barrier Isolation Technology Forum Innovation Updates and New Case Studies 
• Product Quality Lifecycle Implementation 
• Packaging Challenges: Now and in the Future for Investigational and Commercial Products 
• Fully Integrated Approaches to Commissioning, Qualification, and Validation Inclusive of Computer Systems Validation 
• Applied Risk Management – Addressing Cross Industry Challenges 
• Global Supply Chain Security 
• Renovation 
• GAMP® GPG on PCS Ver. 2 and Calibration Guide, Ver. 2

Aptuit's Lois Johnson, Senior Director, Quatlity Assurance will be speaking at this event. The title of her talk will be
Pharmaceutical Outsourcing and Regulatory Oversight – Know Your Agency

For more information and to register to form part of this discussion please visit the event website.

This meeting provides an extremely valuable and truly unique opportunity for Xenobiotic researchers to gather, exchange ideas and expertise. In addition to an outstanding scientific program, which features preclinical aspects, clinical aspects, and new applications of drug development in the 21st century, the ISSX 10th European Regional Meeting provides you with access to state-of-the-art exhibits and poster presentations.

- Aptuit will be exhibiting on stand 51 at this event. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com

Aptuit will be exhibiting at this event. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com

The webinar will cover topics:

Kirsten Ferrandiz, IRT Product Development, Phase Forward

Kirsten Ferrandiz from Phase Forward will present IRT system design strategies to optimize implementation of randomization decisions based on interim analysis of adaptive designs for clinical trials.  She will also explain how planning, coordination and execution across key stakeholders is facilitated through IRT design.

Martyn James, Manager of Operations Support, Aptuit
Chris Brown, Director of Project Management, Aptuit

Martyn and Chris will together explore the topic of the importance of the distribution site to respond quickly and efficiently to the changing requirements of a clinical trial, while minimizing the quantity of pre-labeled product. 
They will also explore the types of studies that just in time labeling is ideally suited for such as, Ph 1/Ph 2/PoC studies where the drug product may be limited by supply and/or cost.

Questions? Contact Joa Haas: joa.haas@aptuit.com or 610-273-7521

SSCI has devoted considerable research and development resources in order to gain a better understanding of amorphous materials and amorphous dispersions. These efforts have resulted in innovative techniques to study and characterize these materials, from generation, to stability, through to scale up. We invite you to join us for a one-day seminar to hear our world renowned experts, including Dr. Jan-Olav Henck, Senior Director of SSCI, discuss the viability and use of amorphous dispersions in drug development as well as the research that has been carried out with regards to amorphous dispersions that is unique to SSCI.

We are honored to have Stephen R. Byrn, Ph. D, Professor of Medicinal Chemistry at Purdue University, discuss regulatory issues related to drug development of amorphous dispersions. Our scientists will also be joined by Eyal Barash, Chief Patent Counsel to Aptuit, to discuss IP issues pertaining to the development of amorphous dispersions and materials.

Seminar Information:
Cost: $200
Thursday, June 10, 2010 - 8:00 am to 4:30 pm
Embassy Suites Hotel - SFO Airport
250 Gateway Blvd
South San Francisco, CA 94080

Register 

Questions?
Call: Colleen Bleczinski at 800-375-2179 x6905
Email: colleen.bleczinski@aptuit.com

Case examples from Europe and the U.S. will be discussed, including Dr. Henck’s report on how Aptuit INDiGO® was implemented in a recent integrated development program.

RSVP by April 27, 2012 to:
bryce.chaney@aptuit.com
This event is free to qualified guests

This event is FREE to qualified guests 

To RSVP to this invitation email nick.johnson@aptuit.com by 20th September 2011

This event is FREE to qualified guests 

To RSVP to this invitation email nick.johnson@aptuit.com by 20th September 2011

This event is FREE to qualified guests 

To RSVP to this invitation email nick.johnson@aptuit.com by 20th September 2011

Case examples from Europe and the U.S. will be discussed, including Dr. Henck’s report on how Aptuit INDiGO® was implemented in a recent integrated development program.

RSVP by April 27, 2012 to:
bryce.chaney@aptuit.com
This event is free to qualified guests

Recent economic pressures and the harsh realties of the risks of early stage drug development have encouraged and, in many cases, forced teams to become much more capital efficient in recent times. Many new variants of more capital efficient models for early stage drug development are evolving and have demonstrated success. Early stage drug development will continue to be risky but the process of generating results is being refined and honed. Less investment dollars are going towards infrastructure and non-critical expenses. Outsourcing, virtualization, and early partnering are all providing new opportunities for early stage drug development.

William D. Kerns DVM, MS, DACVP, President of Aptuit Consulting, will moderate and lead an interactive discussion with some of the area's leading experts, who will compare and contrast different approaches to early stage drug development.

Panel Members: 
Omar Amirana, M.D., Partner, Oxford Bioscience Partners 
D. Davidson Easson Jr., Sc.D., President, Cadrus Therapeutics, Inc. 
Travis Wilson, Esq., Morningside Group and CEO, Stealth Peptides, Inc.

Participant Bios:
William D. Kerns DVM, MS, DACVP, President, Aptuit Consulting Inc.
Dr. Kerns has 30 years of experience in Pharmaceutical Research and Development having held senior executive positions in Preclinical Development at SmithKlineFrench, SmithKlineBeecham and Eisai Pharma during his pharmaceutical career.  He is recognized as an expert in Drug Development and Safety Assessment with focus on mechanisms of drug-induced cardiovascular toxicity.  He has been involved in submitting over 175 INDs and 16 NDAs/MAAs to international authorities and the FDA.  He has authored or co-authored over 100 articles, chapters and abstracts and co-edited a book on cardiovascular toxicology.  He co-chaired an FDA expert committee on biomarkers of drug-induced vascular injury and is currently an advisor to the Critical Path Institute.  Dr Kerns continues to build his consulting practice to deliver drug development services to the biopharmaceutical industry.  The practice is focused on assisting biopharmaceutical companies and investor groups in drug development and regulatory strategy from manufacturing through early Phase 2.

Omar Amirana, M.D., Partner, Oxford Bioscience Partners
Dr. Amirana is a Partner at Oxford Biosciences, focused on healthcare technology investing.  He joined Oxford in 2005 as an Investment Manager with 15 years of industry-related experience in both large and small companies.  He previously served as the Vice President of Business Development at St. Jude Medical focused on electrophysiology, interventional cardiology and peripheral vascular intervention where he was also responsible for a 20 person R&D team.  Prior to joining St. Jude Medical, Dr. Amirana was the CEO of Resolution Medical, a privately held cardiology company in Silicon Valley.  Dr. Amirana has helped raise over $60M in venture financing which resulted in three IPOs: EP Technologies, Cardima, and MedicaLogic/Medscape.  Dr. Amirana was a co-founder of Cardima and served there for seven years as Vice President of Marketing, Business Development and Chief Technology Officer.  He was Vice President of Marketing at MedicaLogic through its IPO which raised $101M and achieved a ~$1.1B market capitalization.  Dr. Amirana has launched cardiovascular products worldwide and holds various patents.  He received a B.S. in Mechanical Engineering from Tufts University and an M.D. from Eastern Virginia Medical School.

D. Davidson Easson Jr., Sc.D., President, Cadrus Therapeutics, Inc.
Dr. Easson is currently President of Cadrus Therapeutics, Inc. a start-up venture developing a novel oral drug delivery technology.  Previously he was VP Manufacturing and Process Development at Epic Therapeutics, Inc., a private drug delivery company which was acquired by Baxter Healthcare Corporation.  Dr. Easson was also General Manager with Collaborative BioAlliance at their Smithfield, RI contract biopharmaceutical manufacturing facility.  Prior to that, Dr. Easson was co-founder and Chief Operating Officer of Alpha-Beta Technology Inc., a public company involved in the development and manufacturing of yeast derived biopharmaceuticals.  He has served on the boards of the UMass Memorial Foundation, the Worcester Business Development Corporation and the Juvenile Diabetes Research Foundation (JDRF) Bay State Chapter.  He also served as a Lay Review Committee member for JDRF International.  In 1993, Dr. Easson was a finalist for Ernst & Young's New England Region Entrepreneur of the Year Award.  He received the Mary Ann Kugel award from JDRF in 2001.  He also received a 2006 Baxter Outstanding Technical Achievement award. Dr. Easson has a B.S. in chemical engineering from the University of South Carolina and a Sc.D. in biochemical engineering from MIT.

Travis Wilson, Esq., Morningside Group and CEO, Stealth Peptides, Inc.
Travis Wilson is a member of the Morningside Group, a private investment group founded by the Chan family of Hong Kong.  Morningside invests in private equity and venture capital opportunities worldwide including established and startup life science companies located throughout North America, Europe and Asia Pacific.  Travis provides operational and management oversight to Morningside's portfolio of companies developing drugs across a broad spectrum of therapeutic focus including oncology, cardiology and critical care.  Travis also regularly performs and manages scientific, regulatory and legal due diligence on life science investment opportunities.  He serves as a director on several boards for both preclinical and clinical stage companies.  Currently, Travis is the CEO of Stealth Peptides, a Morningside portfolio company developing compounds that target the mitochondria to treat ischemia reperfusion injury.  As an intellectual property and transactional lawyer by background, Travis has experience supervising and assessing patent portfolios for investment, mergers and acquisitions, co-development and licensing opportunities.

Given the current and foreseeable economic environment, companies from early stage and emerging biotechs to large pharmaceutical firms are being forced to do more with less. In an effort to reduce and/or minimize direct expenditures, outsourcing has become part of many a company’s development strategy eliminating the need to incur long term funding commitments for infrastructure. Numerous options now exist for outsourcing but too often lack integration resulting in limited productivity gains. To address this issue there is a paradigm shift underway in drug development by some in the pharmaceutical industry from what was a FIPCO (fully-integrated pharmaceutical company) model to a VIPNET (virtually-integrated pharmaceutical network) model. Creation of novel business arrangements between sponsors and vendors are giving rise to accelerated development in a virtual world where realization of both time and cost savings are clearly apparent. This seminar will describe the benefits and challenges of virtual drug development along with a novel approach accomplished through a Virtual Drug Development Agent and show how it is created, and operated along with its features and benefits.

The objective of the MCSG conference is to provide a forum for the open exchange of ideas, regulatory changes, technological advances, and information of a non-confidential nature related to clinical supply activities. We strive to promote closer professional relationships among personnel engaged in clinical supply activities as well as encourage closer relationships between the clinical supply group and other segments of the Pharmaceutical/Biotechnology Industry. In keeping with this purpose, exhibitors are encouraged to be educational, communicative, and informative in their exhibit displays and contact with attendees.

Aptuit will be exhibiting at this event. To prearrange a meeting with an Aptuit representative please email info@aptuit.com

This webinar will provide an overview of alternative approaches available to meet the MIST (Metabolites In Safety Testing) requirements.

Regulatory guidelines on MIST have clearly addressed the need to ensure that the safety of metabolites found in humans is evaluated adequately. An early understanding of the efficacy and toxicity profile of new chemical entities and the contributions of their metabolites has therefore become increasingly important in the pharmaceutical and scientific community.

In this webinar Silvia Martinucci, DMPK Discipline Leader at Aptuit Verona, will present her expertise and experience in the technological approaches for an early (i.e. Phase I) identification and quantification of human metabolites to design the most effective drug development plan mitigating the risk of delays and optimizing resources.

Register here

The objective of the MCSG conference is to provide a forum for the open exchange of ideas, regulatory changes, technological advances, and information of a non-confidential nature related to clinical supply activities.

Aptuit will attend this conference and have a table top display. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com.

MCSGpride themselves on consistently bringing you the most affordable educational programming specifically designed for the Clinical Supply professional.

Do you want to improve efficiency and innovation in your synthetic route design, development and optimisation?

The efficient conversion of a chemical process into a process for manufacture on tonnage scale has always been of importance in the chemical and pharmaceutical industries. However, in the current economic and regulatory climate, it has become increasingly vital and challenging to do so efficiently.

At the 2010 Organic Process Research & Development Conference, you will hear detailed presentations and case studies from top international chemists. The hand-picked programme of speakers has been put together specifically for an industrial audience. They will discuss the latest issues relating to synthetic route design, development and optimisation in the pharmaceutical, fine chemical and allied fields.

Aptuit will be exhibiting at this event, to prearrange a meeting with an Aptuit representative please contact info@aptuit.com

Click herefor the full program and speakersClick herefor the registration formFriday, April 24, 20098:30 AM - 5:00 PMCoffee and Registration starts at8:00 AM

The Westgate Hotel(800) 524-4802San Diego, CA

Contact: David Bernstein(510) 658-3334 Phone(510) 658-3335 Fax

Date
Monday, December 15, 2008

Time
10:00 a.m. - 4:00 p.m., lunch will be served

Where
Le Méridien Brussels
Carrefour de l'Europe 3
Brussels 1000, Belgium

RSVP
By December 1, 2008 to ipeventsbrussels@finnegan.com. There is no charge to attend
the program. Space is limited. For more information, please contact Barbara Saporiti at
+32 (0)2 646 03 53 or barbara.saporiti@finnegan.com.

Respiratory Drug Delivery 2008 will focus around in-depth discussions of many developing issues surrounding aerosol drug delivery including new therapeutic opportunities and drug design technologies, progress in drug development alongside novel in vitro and in vivo testing methods, regulatory science, and much more. The seminar will also include a scientific poster session and technology exhibition.

Aptuit will attend this conference and have a table top display. If you would like to pre-arrange a meeting with one of our representatives, please email info@aptuit.com.

Drug Development has traditionally been a long and extensive process designed for a staged assessment of the safety, efficacy and manufacture of a drug candidate. Reduction of development costs and cycle-time are vital for the sustainability of the Pharmaceutical industry.

Through an interactive dialogue with experts in the field and pharmaceutical groups, the conference will investigate how the most recent scientific advancements and the most modern technologies are positively impacting on Drug Development.

The Southeastern BIO Investor Forum is the Southeast region's premier life sciences venture capital conference, connecting emerging life science companies with potential investors in a forum that provides meaningful networking opportunities.

Attracting more than 400 attendees, including investors from the Southeast and from around the world, SEBIO showcases 30 emerging life sciences companies from Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, Virginia, and beyond each year.

Since 1999, there have been over 160 presenting companies, over 120 companies participating in the early-stage program and 20 competing in the BIO/Plan Competition. SEBIO participants have gone on to raise over $2.5 billion in public and private funding.

Aptuit are sponsoring this event in 2009 and will have a representative available to discus our business. Please email info@aptuit.com if you would like to prearrange a meeting.

Click here for more information and how to register for the course.

Click here for more information and how to register for this course.

• When are polymorphs important?
• What types of studies are required to characterize polymorphs?
• What should be done to characterize amorphous solids?
• How can stability and rates of transformation be analyzed and predicted?
• How is the polymorph or hydrate present related to stability?
• What specifications should be set and how can analytical procedures for mixtures of solids be developed and validated?
• What is required in a regulatory submission (Q6A) and how should it be approached?

This course will be offered three times throughout 2008.

Arlington, VA– April 8-10, 2008 Click here for full details

Macclesfield, England– April 23-25, 2008 Click here for full details

San Francisco, CA- May 14-15, 2008 Click here for full details

The Society of Toxicology Annual Meeting and ToxExpo attracts over 6,500 of the world's leading scientists, executives and decision-makers. ToxExpo 2010 will be the place attendees can see the cutting-edge technology and services available on the market today, as well as attend the SOT Annual Meeting where they can participate in sessions on the latest scientific developments.

Aptuit will be exhibiting at this event on booth 1400. To prearrange a meeting with one of our Industry experts please email info@aptuit.com

The Society of Toxicology (SOT) 50th Annual Meeting is the largest toxicology meeting and exhibition in the world, with an expected attendance of more than 7,000 scientists from academia, government, and industry from various countries around the globe. From the Plenary Opening Lecture and featured lectures to the wide range of scientific sessions and Continuing Education courses, the Annual Meeting offers an unparalleled depth of analysis and relevant toxicological issues. From basic to advanced topical issues, the thematic approach provides each attendee an opportunity to learn about emerging fields. Whether you are speaking in or chairing a session, honoring a colleague as the recipient of an SOT award, or collaborating with your peers at an SOT event, this meeting has something for every attendee. Plenary speakers include Dr. Francis Collins, Director of National Institutes of Health, Dr. Margaret Hamburg, U.S. Food and Drug Administration (U.S. FDA) Commissioner, and Lisa Jackson, U.S. Environmental Protection Agency (U.S. EPA) Administrator.
 

Aptuit will be attending this event and will be exhibiting at booth #621

To arrange a meeting with us please send an e-mail to: info@aptuit.com

June 15th, 2011
Time: 11:30 AM-1:30 PM

Solid-state chemistry plays an important role in the drug development process. After
candidate selection, a screening effort for different solid forms will provide you with a
number of options. From the different forms found, you may then select the form that
has the desired properties you are looking for in your candidate. SSCI will discuss
how different screening efforts and techniques will affect your options as well as ways
of overcoming solubility issues by utilizing, for example, cocrystals and amorphous
dispersions, to enable early development milestones.

Aptuit will be hosting this event - it is free to qualified guests.

If you interested in registering for the event, please send an e-mail to ilia.jimenez@aptuit.com by June 8th, 2011

Solid-state chemistry plays an important role in the drug development process. After
candidate selection, a screening effort for different solid forms will provide you with a
number of options. From the different forms found, you may then select the form that
has the desired properties you are looking for in your candidate. SSCI will discuss
how different screening efforts and techniques will affect your options as well as ways
of overcoming solubility issues by utilizing, for example, cocrystals and amorphous
dispersions, to enable early development milestones.

Aptuit will be hosting this event - it is free to qualified guests.

If you interested in registering for the event, please send an e-mail to ilia.jimenez@aptuit.com by June 8th, 2011

The theme of this course is using solid state chemistry to support drug development. Thus, the course will outline strategies to achieve stable drug products using modern solid state chemistry. We believe that solid state chemistry provides a powerful strategy to design stable drug products very early in the development process.

US Short Course:
Hyatt at The Bellevue
Philadelphia, PA
April 5 & 6, 2011

Click here to register

This U.S. FDA co-sponsored WCBP Symposium series is the pre-eminent conference addressing the analytical development/regulatory control interface for biotechnology derived health intervention products. The goal of this Symposium series is to provide a forum for discussing the latest bioanalytical methods and their practical application to biotechnology pharmaceuticals and other health related products. Both state-of-the-art innovations as well as conventional technologies addressing research and routine testing applications will be covered. This includes both method and instrumental advances that are used for product characterization, process development, in-process analysis and validate release & stability testing

Aptuit will be exhibiting on booth 20 in the exhibition hall, if you would like to prearrange a meeting with an Aptuit representative please email info@aptuit.com

This U.S. FDA co-sponsored WCBP Symposium series is the pre-eminent conference addressing the analytical development/regulatory control interface for biotechnology derived health intervention products. The goal of this Symposium series is to provide a forum for discussing the latest bioanalytical methods and their practical application to biotechnology pharmaceuticals and other health related products. Both state-of-the-art innovations as well as conventional technologies addressing research and routine testing applications will be covered. This includes both method and instrumental advances that are used for product characterization, process development, in-process analysis and validate release & stability testing

Aptuit will be exhibiting in the exhibition hall, if you would like to prearrange a meeting with an Aptuit representative please email info@aptuit.com

Click here to register

Click here to register